BMCCancerannounces a major achievement –
the publication of its 1,000^tharticle.BMCCanceris the second medical journal in theBMC–seriesto achieve this milestone in 2008, afterBMCPublic Health, and follows in the footsteps ofBMCBioinformaticsandBMCGenomics, which surpassed one thousand
publications in 2006 and 2007 respectively.

The1,000^th
article‘Importance of
response to neoadjuvant chemotherapy in potentially curable colorectal cancer
liver metastases’由Birgit Gruenberger及其医疗的同事
University Vienna reports that oxaliplatin-based chemotherapy can reduce the
risk of recurrence after liver resection in patients treated for liver
metastases arising from colorectal cancer. The article has already been
accessed over 900 times.

BMCCanceris grateful to Dr Gruenberger
and her colleagues for their valued contributions: this is Dr Gruenberger’s
second publication in the journal, and she has served as an ad hoc reviewer.

The editors ofBMCCancerwould like to take this opportunity to thank all the authors and
reviewers who have contributed to the journal’s growth since it was launched in
2001. Special thanks go to those authors who have shown their confidence in our
open access model and our rigorous peer review process by continuing to submit regular
contributions to the journal.

Particular credit in the journal’s
trajectory is due to ourinternational Editorial
Board, which has provided continuous support and editorial advice during
the last few years. Our Editorial Board members have invested their time and
interest in order to ensure thatBMCCancercontinues to
attract the attention of both basic science researchers and clinical oncologists.

BMCCancer刚刚收到2007年
汤森科学（ISI）的影响因素，非常
respectable2.71, up from the 2.36
rate earned last year.

This improving impact factor reflects the
journal’s increasing standing in the field of cancer research andBMCCancer’s commitment to provide high visibility for its authors’ work. Thetop ten most viewed articleshave received
over 100,000 accesses, while the top ten articles published in the journal在过去的30天中被引用了
almost 5,000 times.

BMC
Canceroffers an attractive venue for the
传播所有类型的癌症研究。该期刊认为文章
covering cell or molecular biology studies, genetic research, pathophysiology,
epidemiological and clinical reports as well as clinical trials related to cancer
or patients suffering from this condition.

We invite you to considerBMCCancer为了发表您的下一篇研究文章；你可以submit
your workeasily and quickly onlinevia the journal website.

If you have any questions aboutBMCCancer或者如果你would like to
be involved in the journal, as
an author, reviewer, or Associate Editor, pleasedo
get in touch.

IratxePuebla

In-house EditorBMCCancer